Insider Cluster (2 insiders) ·Filed Sep 4, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed27d 10h ago
Insider cluster: 2 insiders, $192K total
Actionable Insight • Neutral

This insider sale cluster is too small to be informative — monitor for larger insider activity or upcoming catalysts like clinical trial data readouts. The company's strong analyst consensus (92% bullish) and prior insider buying patterns (multiple signal_insider_buy events in July 2026) suggest this selling is likely liquidity-driven rather than signaling fundamental concerns.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+1d
ARTV ▼ -2.77% at T+1d
NEUTRAL call ✗ call lost -2.77% · α vs SPY -2.22% · entry $11.19 → $10.88
Next anchor: T+5d due 21d ago
Latest observation: T+17 -55.41% FF3 residual α
Entry anchored
Sep 3, 04:26 PM ET
via 1-min bar
T+1d
-2.77%
call -2.77% · α -2.22%
$10.88
settled 28d ago
T+5d
—
call — · α —
—
due 21d ago
T+20d
—
call — · α —
—
due 4h ago
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Two C-suite insiders at Artiva Biotherapeutics (COO/CLO and CMO) sold a combined $192K in open-market sales over a 7-day window. The total value represents just 0.035% of the company's $544M market cap, making this a routine and immaterial cluster of insider sales with no predictive signal.

Key Financial Metrics

Direction
selling
Total Value
$192.0K
Insiders
2

Key Facts

  • COO/CLO Jennifer Bush sold 8,391 shares at $11.16 for $94K on 2026-09-03
  • CMO Subhashis Banerjee sold 8,200 shares at $12.01 for $99K on 2026-08-27
  • Total insider sales of $192K represent only 0.035% of ARTV's $544M market cap
  • Both sales were open-market transactions (code S), not tax-withholding or exercise-related

Financial Impact

Total insider sales of $192K, representing 0.035% of market cap — immaterial

dilution

Risk Factors

  • Insider selling could accelerate if clinical trial results disappoint
  • Biotech sector binary risk around pipeline milestones

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ARTV-1788588440257
28 reports for ARTV
Performance horizon
88% Hit rate 14 of 16 directional calls best @ T+20▲ +38.82%Jun 8, 2026
Filters
Rows
Reports for ARTV — sortable, filterable
TypeNow
Sep 11, 2026
20d ago
8-K
NEUTRAL ★ 3/10
$10.14 $8.91▼ −12.13%▼ −11.67%$6.86 (−32.35%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 4/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$10.79 $10.42▼ −3.43%▼ −2.83%$6.86 (−36.42%)
Sep 9, 2026
23d ago
Insider Cluster
BEARISH ★ 5/10
$10.79 $10.42▲ +3.43%▲ +2.83%$6.86 (+36.42%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$11.19 $10.88▼ −2.77%▼ −2.22%$6.86 (−38.70%)
Aug 15, 2026
6w ago
Institutional Cluster
BULLISH ★ 6/10
$11.74 $11.68▼ −0.51%▲ +0.16%$6.86 (−41.57%)
Jul 31, 2026
8w ago
Insider Buy
BULLISH ★ 7/10
$10.76 $11.07▲ +2.88%▲ +1.08%$6.86 (−36.25%)
Jul 28, 2026
9w ago
Insider Buy
BULLISH ★ 6/10
$10.53 $10.02▼ −4.84%▼ −3.30%$6.86 (−34.85%)
Showing 10 of 28

US Market Status

Market Open — Closes in 3h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 5, 2026